Motor impairment produced by ethanol and site-selective NMDA receptor antagonists in micetolerance and cross-tolerance

Alcohol

Volumn 20, Issue 1, 2000, Pages 31-36

  Neznanova, Olga N ^a   Blokhina, Elena A ^a   Sukhotina, Irina A ^a   Bespalov, Anton Y ^a  

^a PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Cross tolerance; D CPPene (SDZ EAA 494); Ethanol; Memantine; Mice; NMDA receptor antagonists; Rotarod; Tolerance

Indexed keywords

4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; ALCOHOL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CROSS TOLERANCE; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG TOLERANCE; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; ROTAROD TEST;

ANIMALS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DRUG INTERACTIONS; DRUG TOLERANCE; ETHANOL; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MEMANTINE; MICE; MOTOR SKILLS; PIPERAZINES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0033966345     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-8329(99)00053-1     Document Type: Article

References (35)

1. Balster R.L., Willetts J. Phencyclidine. a drug of abuse and a tool for neuroscience research Schuster C.R., Kuhar M.J. Pharmacological Aspects of Drug Dependence. Towards an Integrated Neurobehavioral Approach. Handbook of Experimental Pharmacology, Vol. 118:1996;233-262 Springer-Verlag, Berlin.
2. Boast C.A., Pastor G., Gerhardt S.C., Hall N.R., Liebman J.M. Behavioral tolerance and sensitization to CGS 19755, a competitive N-methyl-D-aspartate receptor antagonist. J Pharmacol Exp Ther. 247:1988;556-561.
3. Collins A.C., Burch J.B., de Fiebre C.M., Marks M.J. Tolerance to and cross tolerance between ethanol and nicotine. Pharmacol Biochem Behav. 29:1988;365-373.
4. Colombo G., Grant K.A. NMDA receptor complex antagonists have ethanol-like discriminative stimulus effects. Ann NY Acad Sci. 654:1992;421-423.
5. Commissaris R.L., Rech R.H. Tolerance and cross-tolerance to central nervous system depressants after chronic pentobarbital or chronic methaqualone administration. Pharmacol Biochem Behav. 18:1983;327-331. 1983.
6. Danysz W., Parsons C.G. Glycine and NMDA receptorsphysiological significance and possible therapeutic applications. Pharmacol Rev. 50:1998;597-664.
7. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agentspreclinical studies. Neurosci Biobehav Rev. 21:1997;455-468.
8. Follesa P., Ticku M.K. Chronic ethanol-mediated up-regulation of the N-methyl-D-aspartate receptor polypeptide subunits in mouse cortical neurons in culture. J Biol Chem. 271:1996;13297-13299. a.
9. Follesa P., Ticku M.K. NMDA receptor upregulation. molecular studies in cultured mouse cortical neurons after chronic antagonist exposure J Neurosci. 16:1996;2172-2178. b.
10. Grant K.A., Valverius P., Hudspith M., Tabakoff B. Ethanol withdrawal seizures and the NMDA receptor complex. Eur J Pharmacol. 176:1990;289-296.
11. Gulya K., Grant K.A., Valverius P., Hoffman P.L., Tabakoff B. Brain regional specificity and time-course of changes in the NMDA receptor-ionophore complex during ethanol withdrawal. Brain Res. 547:1991;129-134.
12. Henkel J.G., Hane J.T., Gianutsos G. Structure antiparkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution. J Med Chem. 25:1982;51-56.
13. Heresco-Levy U., Javitt D.C. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol. 8:1998;141-152.
14. Herrling P.L., Emre M., Watkins J.C. D-CPPene (SDZ EAA-494)a competitive NMDA receptor antagonist. pharmacology and results in humans Herrling P.L. Excitatory Amino AcidsClinical Results with Antagonists. 1997;7-21 Academic Press, San Diego, CA.
15. Hesselink M.B., Smolders H.G., De Boer A.G., Breimer D.D., Danysz W. Modifications of the behavioural profile of uncompetitive NMDA receptor antagonist, memantine, amantadine and (+)MK-801 after chronic administration. Behav Pharmacol. 10:1999;85-98.
16. Jessa M., Nazar M., Bidzinski A., Plaznik A. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. Eur Neuropsychopharmacol. 6:1996;55-61.
17. Kim C.K., Pinel J.P.J., Dalal S., Kippin T.E., Kalynchuk L.E., Payne G.J. Contingent drug tolerance. differential tolerance to the anticonvulsant, hypothermic, and ataxic effects of ethanol Pharmacol Biochem Behav. 52:1995;531-539.
18. Khanna J.M., Le A.D., Kalant H., Chau A., Shah G. Effect of lipid solubility on the development of chronic cross-tolerance between ethanol and different alcohols and barbiturates. Pharmacol Biochem Behav. 57:1997;101-110.
19. Kumar R., Stolerman I.P. Experimental and clinical aspects of drug dependence. Iverson L.L., Iverson S.D., Snyder S.H. Principles of Behavioral Pharmacology, Vol. 7. 1977;321-367 Plenum Press, New York.
20. Liljequist S. The competitive NMDA receptor antagonist, CGP 39551, inhibits ethanol withdrawal seizures. Eur J Pharmacol. 192:1991;197-198.
21. Lovinger D. Alcohols and neurotransmitter gated ion channels. Naunyn-Schmied Arch Pharmacol. 356:1997;267-282.
22. Lu Y., France C.P., Woods J.H. Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons. cross-tolerance between PCP-like compounds and competitive NMDA antagonists J Pharmacol Exp Ther. 263:1992;499-504.
23. Rabbani M., Wright E.J., Little H.J. Tolerance to competitive NMDA antagonists, but no crosstolerance with barbiturates. Pharmacol Biochem Behav. 50:1995;9-15.
24. Siemens A.J., Doyle O.L. Cross-tolerance between delta9-tetrahydrocannabinol and ethanol. the role of drug disposition Pharmacol Biochem Behav. 10:1979;49-55.
25. Skolnick P., Miller R., Young A., Boje K., Trullas R. Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex. Psychopharmacol. 107:1992;489-496.
26. Smith S.E., Chapman A.G. Acute and chronic anticonvulsant effects of D(-) CPPene in genetically epilepsy-prone rats. Epilepsy Res. 15:1993;193-199.
27. Snell L.D., Tabakoff B., Hoffman P.L. Radioligand binding to the N-methyl-D-aspartate receptor/ionophore complex. alterations by ethanol in vitro and by chronic in vivo ethanol ingestion Brain Res. 602:1993;91-98.
28. Sprague G.L., Craigmill A.L. Ethanol and delta-9-tetrahydrocannabinol. mechanism for cross-tolerance in mice Pharmacol Biochem Behav. 5:1976;409-415.
29. Trevisan L., Fitzgerald L.W., Brose N., Gasic G.P., Heinemann S.F., Duman R.S., Nestler E.J. Chronic ingestion of ethanol up-regulates NMDAR1 receptor subunit immunoreactivity in rat hippocampus. J Neurochem. 62:1994;1635-1638.
30. Tsai G., Gastfrield D.R., Coyle J.T. The glutamatergic basis of human alcoholism. Am J Psychiatry. 152:1995;332-340.
31. Urwyler S., Campbell E., Fricker G., Jenner P., Lemaire M., McAllister K.H., Neijt H.C., Park C.K., Perkins M., Rudin M., Sauter A., Smith L., Wiederhold K.H., Muller W. Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonistsII. Pharmacological characterization in vivo. Neuropharmacol. 35:1996;655-669.
32. Uzbay I.T., Kayaalp S.O. Heterogeneity of tolerance developed to effects of ethanol on rotarod and accelerod performances in rats. Alcohol. 12:1995;593-595.
33. Van Amsterdam C., Lemaire M. Pharmacokinetic profile of SDZ EAA 494 in blood, brain and CSF using microdialysis. Eur J Pharm Sci. 5:1997;109-116.
34. Willetts J., Clissold D.B., Hartman T.L., Brandsgaard R.R., Hamilton G.S., Ferkany J.W. Behavioral pharmacology of NPC 17742, a competitive N-methyl-D-aspartate (NMDA) antagonist. J Pharmacol Exp Ther. 265:1993;1055-1062.
35. Williams K., Dichter M.A., Molinoff P.B. Up-regulation of N-methyl-D-aspartate receptors on cultured cortical neurons after exposure to antagonists. Mol Pharmacol. 42:1992;147-151.